Sun Pharma, Ranbaxy Inc sign pact with 2 plaintiff groups to settle claims

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously


claim settlement | Sun Pharma | Ranbaxy

Sun Pharmaceutical Industries Ltd on Wednesday said it along with its US-based arm Ranbaxy, Inc, has

signed a USD 485 million settlement with two plaintiff groups regarding Ranbaxy generic drug application antitrust litigation.

The company and its arm have signed a binding term sheet with two plaintiff groups, the Direct Purchaser and End-Payor Plaintiffs, collectively resolving all of the claims against the company, in the matter of “In re Ranbaxy Generic Drug Application Antitrust Litigation”, Sun Pharma said in a regulatory filing.

The case has been ongoing in the U.S. District Court for the District of Massachusetts (USA) for several years, it added.

There were multiple antitrust, consumer protection, and civil RICO class actions consolidated in the District of Massachusetts, (USA) against the Company in connection with generic Diovan, a drug for the treatment of hypertension; generic Nexium, a drug for the treatment of gastroesophageal reflux disease and peptic ulcers; and generic Valcyte, a drug for the treatment of cytomegalovirus disease, it added.

The actions and claims relate to alleged conduct by Ranbaxy Laboratories Ltd. and its U.S. subsidiary prior to its acquisition by Sun Pharmaceutical Industries Ltd, the company said.

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously.

“With a view to resolve this dispute and avoid uncertainty, the company has agreed to enter a comprehensive settlement with these plaintiff groups for a total settlement amount of USD 485 million,” it said.

As a consequence of the binding term sheet, the company shall execute the necessary settlement agreements, which, upon approval by the US Court, will ensure that all allegations against it has denied, is “not conceded and not admitted, do not survive and stand extinguished”.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor